Growth in use of lipid-lowering therapies: Are we targeting the right patients?

American Journal of Managed Care

Volumn 8, Issue 10, 2002, Pages 862-867

  Dubois, Robert W ^a   Alexander, Charles M ^a   Wade, Sally ^a   Mosso, Andrew ^a   Markson, Leona ^a   Lu, J D ^a   Nag, Soma ^a   Berger, Marc L ^a  

^a Zynx Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BILE SALT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; OMEGA 3 FATTY ACID; PROBUCOL;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DRUG INDUSTRY; DRUG MARKETING; DRUG UTILIZATION; FEMALE; GENDER; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INSURANCE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAL DOCUMENTATION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY PREVENTION;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DRUG UTILIZATION REVIEW; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; HYPERLIPIDEMIAS; MALE; MANAGED CARE PROGRAMS; NEEDS ASSESSMENT; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 0036799310     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Health Care Financing Administration. National health expenditures aggregate amounts and average annual percent change, by type of expenditure: Selected calendar years 1980-2000. http://www.hcfa.gov/stats/nhe-oact/tables/t2.htm Accessed January 2, 2001.
2. Health Care Financing Administration. Available at: http://www.cms.hhs.gov/statistics/nhe/projections-2001/t2.asp. Accessed August 27, 2002.
3. Dubois RW, Chawla AJ, Neslusan CA, Smith MW, Wade S. Explaining drug spending trends: Does perception match reality? Health Aff. 2000;19(2):231-239.
4. Employee Benefit Research Institute (EBRI). Prescription Drugs: Issues of Costs, Coverage, and Quality. Washington DC: Employee Benefit Research Institute; April 1999. EBRI Issue Brief 208.
5. Teitelbaum et al. Drug Trend Report, 1998. Maryland Heights, Mo: Express Scripts; 1999.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
7. Pearson TA, Peters TD. The treatment gap in coronary artery disease and heart failure: Community standards and the post-discharge patient. Am J Cardiol. 1997;80:45H-52H.
8. Sueta CA, Chowdhury M, Boccuzzi, SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83:1303-1307.
9. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction data from the National Registry of Myocardial Infarction 3. Circulation. 2001;103:38-44.
10. Abookire SA, Karson AS, Fisko J, Bates DW. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med. 2001;161:53-58.
11. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation. 1996;93:1796-1802.
12. Jonsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of cholesterol lowering: Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J. 1996;17:1001-1007.
13. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997;336:332-336.
14. Herman WH, Alexander CM, Cook JR, et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes: Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care. 1999;22:1771-1778.